Today's Analyst Stock Ratings | Upgrades, Downgrades

							Get Alert
Sep 8, 2026	ALNYAlnylam Pharmaceuticals	$243.38	6.83%	Faisal KhurshidJefferies 74%	230 260	Previous Hold Current Hold	Get Alert
Sep 2, 2026	ALNYAlnylam Pharmaceuticals	$243.38	86.95%	Patrick R. TrucchioHC Wainwright & Co. 75%	455 455	Previous Buy Current Buy	Get Alert
Aug 19, 2026	ALNYAlnylam Pharmaceuticals	$243.38	30.66%	David LebowitzBMO Capital 68%	318	Previous Initiates Current Outperform	Get Alert
Aug 14, 2026	ALNYAlnylam Pharmaceuticals	$243.38	5.19%	Derek ArchilaWells Fargo 82%	256 316	Previous Equal-Weight Current Equal-Weight	Get Alert
Aug 4, 2026	ALNYAlnylam Pharmaceuticals	$243.38	29.43%	Danielle BrillTruist Securities 72%	315 410	Previous Buy Current Buy	Get Alert
Aug 4, 2026	ALNYAlnylam Pharmaceuticals	$243.38	86.95%	Patrick R. TrucchioHC Wainwright & Co. 75%	455 485	Previous Buy Current Buy	Get Alert
Aug 3, 2026	ALNYAlnylam Pharmaceuticals	$243.38	72.57%	Martin AusterRaymond James 76%	420 420	Previous Outperform Current Strong Buy	Get Alert
Aug 3, 2026	ALNYAlnylam Pharmaceuticals	$243.38	39.7%	Eric JosephCitigroup 51%	340 380	Previous Buy Current Buy	Get Alert
Aug 3, 2026	ALNYAlnylam Pharmaceuticals	$243.38	84.9%	Eliana MerleBarclays 65%	450 527	Previous Overweight Current Overweight	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	54.08%	Jessica FyeJP Morgan 68%	375 400	Previous Overweight Current Overweight	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	43.81%	Luca IssiRBC Capital 63%	350 445	Previous Outperform Current Outperform	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	23.26%	Michael UlzMorgan Stanley 66%	300 400	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	43.81%	Kostas BiliourisOppenheimer 34%	350 500	Previous Outperform Current Outperform	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	29.84%	Derek ArchilaWells Fargo 82%	316 377	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	30.66%	Paul MatteisStifel 57%	318 444	Previous Buy Current Buy	Get Alert
Jul 31, 2026	ALNYAlnylam Pharmaceuticals	$243.38	74.62%	Keay NakaeChardan Capital 70%	425 425	Previous Buy Current Buy	Get Alert
Jul 30, 2026	ALNYAlnylam Pharmaceuticals	$243.38	46.68%	Joseph StringerNeedham 69%	357 510	Previous Buy Current Buy	Get Alert
Jul 22, 2026	ALNYAlnylam Pharmaceuticals	$243.38	64.35%	Jessica FyeJP Morgan 68%	400 420	Previous Overweight Current Overweight	Get Alert
Jul 14, 2026	ALNYAlnylam Pharmaceuticals	$243.38	68.46%	Tazeen AhmadB of A Securities 60%	410 460	Previous Buy Current Buy	Get Alert
Jul 13, 2026	ALNYAlnylam Pharmaceuticals	$243.38	68.46%	Danielle BrillTruist Securities 72%	410 505	Previous Buy Current Buy	Get Alert
Jul 13, 2026	ALNYAlnylam Pharmaceuticals	$243.38	99.28%	Patrick R. TrucchioHC Wainwright & Co. 75%	470 485	Previous Buy Current Buy	Get Alert
Jul 10, 2026	ALNYAlnylam Pharmaceuticals	$243.38	64.35%	Michael UlzMorgan Stanley 66%	370 400	Previous Equal-Weight Current Equal-Weight	Get Alert
Jun 29, 2026	ALNYAlnylam Pharmaceuticals	$243.38	93.11%	Patrick R. TrucchioHC Wainwright & Co. 75%	470 510	Previous Buy Current Buy	Get Alert
Jun 4, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Patrick R. TrucchioHC Wainwright & Co. 75%	510 510	Previous Buy Current Buy	Get Alert
May 19, 2026	ALNYAlnylam Pharmaceuticals	$243.38	56.13%	Eric JosephCitigroup 51%	380	Previous Initiates Current Buy	Get Alert
May 5, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Patrick R. TrucchioHC Wainwright & Co. 75%	510 510	Previous Buy Current Buy	Get Alert
May 1, 2026	ALNYAlnylam Pharmaceuticals	$243.38	82.84%	Luca IssiRBC Capital 63%	445 450	Previous Outperform Current Outperform	Get Alert
May 1, 2026	ALNYAlnylam Pharmaceuticals	$243.38	54.9%	Derek ArchilaWells Fargo 82%	376 377	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 13, 2026	ALNYAlnylam Pharmaceuticals	$243.38	107.49%	Danielle BrillTruist Securities 72%	505 515	Previous Buy Current Buy	Get Alert
Mar 25, 2026	ALNYAlnylam Pharmaceuticals	$243.38	74.62%	Keay NakaeChardan Capital 70%	425 425	Previous Buy Current Buy	Get Alert
Mar 25, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Patrick R. TrucchioHC Wainwright & Co. 75%	510 510	Previous Buy Current Buy	Get Alert
Mar 16, 2026	ALNYAlnylam Pharmaceuticals	$243.38	35.59%	Faisal KhurshidJefferies 74%	330 522	Previous Buy Current Hold	Get Alert
Feb 18, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Patrick R. TrucchioHC Wainwright & Co. 75%	510 510	Previous Buy Current Buy	Get Alert
Feb 17, 2026	ALNYAlnylam Pharmaceuticals	$243.38	68.46%	Ilya ZubkovFreedom Broker 53%	410 470	Previous Hold Current Buy	Get Alert
Feb 17, 2026	ALNYAlnylam Pharmaceuticals	$243.38	76.27%	Whitney IjemCanaccord Genuity 68%	415 429	Previous Buy Current Buy	Get Alert
Feb 13, 2026	ALNYAlnylam Pharmaceuticals	$243.38	74.62%	Keay NakaeChardan Capital 70%	425 475	Previous Buy Current Buy	Get Alert
Feb 12, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Joseph StringerNeedham 69%	510 529	Previous Buy Current Buy	Get Alert
Jan 30, 2026	ALNYAlnylam Pharmaceuticals	$243.38	67.64%	Michael UlzMorgan Stanley 66%	408 495	Previous Equal-Weight Current Equal-Weight	Get Alert
Jan 30, 2026	ALNYAlnylam Pharmaceuticals	$243.38	89.83%	Tazeen AhmadB of A Securities 60%	462 529	Previous Buy Current Buy	Get Alert
Jan 30, 2026	ALNYAlnylam Pharmaceuticals	$243.38	109.55%	Patrick R. TrucchioHC Wainwright & Co. 75%	510 570	Previous Buy Current Buy	Get Alert
Jan 28, 2026	ALNYAlnylam Pharmaceuticals	$243.38	116.53%	Eliana MerleBarclays 65%	527	Previous Initiates Current Overweight	Get Alert
Jan 20, 2026	ALNYAlnylam Pharmaceuticals	$243.38	91.06%	Luca IssiRBC Capital 63%	465 500	Previous Outperform Current Outperform	Get Alert
Jan 20, 2026	ALNYAlnylam Pharmaceuticals	$243.38	54.49%	Derek ArchilaWells Fargo 82%	376 479	Previous Equal-Weight Current Equal-Weight	Get Alert
Jan 12, 2026	ALNYAlnylam Pharmaceuticals	$243.38	117.36%	Tazeen AhmadB of A Securities 60%	529 530	Previous Buy Current Buy	Get Alert
Jan 12, 2026	ALNYAlnylam Pharmaceuticals	$243.38	117.36%	Joseph StringerNeedham 69%	520 529	Previous Buy Current Buy	Get Alert
Jan 8, 2026	ALNYAlnylam Pharmaceuticals	$243.38	117.77%	Danielle BrillTruist Securities 72%	530 535	Previous Buy Current Buy	Get Alert
Dec 15, 2025	ALNYAlnylam Pharmaceuticals	$243.38	44.22%	Mani ForooharLeerink Partners 48%	351 370	Previous Market Perform Current Market Perform	Get Alert
Dec 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	108.73%	Paul MatteisStifel 57%	495 508	Previous Buy Current Buy	Get Alert
Nov 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	96.81%	Derek ArchilaWells Fargo 82%	395 479	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 5, 2025	ALNYAlnylam Pharmaceuticals	$243.38	93.11%	Ilya ZubkovFreedom Broker 53%	230 470	Previous Buy Current Buy	Get Alert
Oct 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	100.92%	Edward TenthoffPiper Sandler 59%	449 489	Previous Overweight Current Overweight	Get Alert
Oct 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	116.53%	Gena WangBarclays 54%	460 527	Previous Overweight Current Overweight	Get Alert
Oct 30, 2025	ALNYAlnylam Pharmaceuticals	$243.38	125.57%	Maury RaycroftJefferies 41%	549 550	Previous Buy Current Buy	Get Alert
Oct 17, 2025	ALNYAlnylam Pharmaceuticals	$243.38	119.82%	Danielle BrillTruist Securities 72%	459 535	Previous Buy Current Buy	Get Alert
Oct 13, 2025	ALNYAlnylam Pharmaceuticals	$243.38	94.35%	Jessica FyeJP Morgan 68%	473 475	Previous Overweight Current Overweight	Get Alert
Oct 10, 2025	ALNYAlnylam Pharmaceuticals	$243.38	134.2%	Patrick R. TrucchioHC Wainwright & Co. 75%	570 570	Previous Buy Current Buy	Get Alert
Oct 6, 2025	ALNYAlnylam Pharmaceuticals	$243.38	95.17%	Michael UlzMorgan Stanley 66%	405 475	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 6, 2025	ALNYAlnylam Pharmaceuticals	$243.38	103.39%	Paul MatteisStifel 57%	441 495	Previous Buy Current Buy	Get Alert
Sep 19, 2025	ALNYAlnylam Pharmaceuticals	$243.38	105.44%	Luca IssiRBC Capital 63%	435 500	Previous Outperform Current Outperform	Get Alert
Sep 17, 2025	ALNYAlnylam Pharmaceuticals	$243.38	113.66%	Tazeen AhmadB of A Securities 60%	453 520	Previous Buy Current Buy	Get Alert
Sep 16, 2025	ALNYAlnylam Pharmaceuticals	$243.38	132.56%	Salveen RichterGoldman Sachs 65%	504 566	Previous Buy Current Buy	Get Alert
Sep 15, 2025	ALNYAlnylam Pharmaceuticals	$243.38	125.98%	Maury RaycroftJefferies 41%	453 550	Previous Buy Current Buy	Get Alert
Sep 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	111.62%	Liisa BaykoEvercore ISI Group 72%	280 515.05	Previous Outperform Current Outperform	Get Alert
Sep 8, 2025	ALNYAlnylam Pharmaceuticals	$243.38	93.11%	Kostas BiliourisBMO Capital 34%	450 470	Previous Outperform Current Outperform	Get Alert
Sep 2, 2025	ALNYAlnylam Pharmaceuticals	$243.38	134.2%	Patrick R. TrucchioHC Wainwright & Co. 75%	570 570	Previous Buy Current Buy	Get Alert
Sep 2, 2025	ALNYAlnylam Pharmaceuticals	$243.38	139.54%	David LebovitzCitigroup 66%	527 583	Previous Buy Current Buy	Get Alert
Aug 7, 2025	ALNYAlnylam Pharmaceuticals	$243.38	134.2%	Patrick TrucchioHC Wainwright & Co. 68%	500 570	Previous Buy Current Buy	Get Alert
Aug 6, 2025	ALNYAlnylam Pharmaceuticals	$243.38	95.17%	Jessica FyeJP Morgan 68%	348 475	Previous Overweight Current Overweight	Get Alert
Aug 4, 2025	ALNYAlnylam Pharmaceuticals	$243.38	101.33%	Leland GershellOppenheimer 74%	490	Previous Perform Current Outperform	Get Alert
Aug 4, 2025	ALNYAlnylam Pharmaceuticals	$243.38	—	Andy ChenWolfe Research 70%	—	Previous Underperform Current Peer Perform	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	84.9%	Greg HarrisonScotiabank 78%	342 450	Previous Sector Outperform Current Sector Outperform	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	125.98%	Eliana MerleUBS 65%	403 550	Previous Buy Current Buy	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	70.52%	Whitney IjemCanaccord Genuity 68%	390 415	Previous Buy Current Buy	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	62.3%	Tiago FauthWells Fargo 58%	333 395	Previous Equal-Weight Current Equal-Weight	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	74.21%	Martin AusterRaymond James 76%	370 424	Previous Outperform Current Outperform	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	89%	Gena WangBarclays 54%	329 460	Previous Overweight Current Overweight	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	84.49%	Edward TenthoffPiper Sandler 59%	304 449	Previous Overweight Current Overweight	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	64.35%	Keay NakaeChardan Capital 70%	325 400	Previous Buy Current Buy	Get Alert
Aug 1, 2025	ALNYAlnylam Pharmaceuticals	$243.38	66.41%	Michael UlzMorgan Stanley 66%	312 405	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	96.4%	Joseph StringerNeedham 69%	377 478	Previous Buy Current Buy	Get Alert
Jul 29, 2025	ALNYAlnylam Pharmaceuticals	$243.38	52.03%	Martin AusterRaymond James 76%	308 370	Previous Outperform Current Outperform	Get Alert
Jul 21, 2025	ALNYAlnylam Pharmaceuticals	$243.38	58.19%	Danielle BrillTruist Securities 72%	385	Previous Initiates Current Buy	Get Alert
Jul 16, 2025	ALNYAlnylam Pharmaceuticals	$243.38	42.99%	Jessica FyeJP Morgan 68%	338 348	Previous Overweight Current Overweight	Get Alert
Jul 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	66%	David LebovitzCitigroup 66%	364 404	Previous Buy Current Buy	Get Alert
Jul 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	47.51%	Tazeen AhmadB of A Securities 60%	336 359	Previous Buy Current Buy	Get Alert
Jul 7, 2025	ALNYAlnylam Pharmaceuticals	$243.38	57.78%	Maury RaycroftJefferies 41%	328 384	Previous Buy Current Buy	Get Alert
Jun 30, 2025	ALNYAlnylam Pharmaceuticals	$243.38	36.82%	Tiago FauthWells Fargo 58%	287 333	Previous Equal-Weight Current Equal-Weight	Get Alert
Jun 26, 2025	ALNYAlnylam Pharmaceuticals	$243.38	54.9%	Joseph StringerNeedham 69%	320 377	Previous Buy Current Buy	Get Alert
Jun 24, 2025	ALNYAlnylam Pharmaceuticals	$243.38	47.92%	Kostas BiliourisBMO Capital 34%	300 360	Previous Outperform Current Outperform	Get Alert
Jun 12, 2025	ALNYAlnylam Pharmaceuticals	$243.38	38.88%	Jessica FyeJP Morgan 68%	330 338	Previous Overweight Current Overweight	Get Alert
May 2, 2025	ALNYAlnylam Pharmaceuticals	$243.38	43.4%	Eliana MerleUBS 65%	331 349	Previous Buy Current Buy	Get Alert
May 2, 2025	ALNYAlnylam Pharmaceuticals	$243.38	33.54%	Keay NakaeChardan Capital 70%	300 325	Previous Buy Current Buy	Get Alert
Apr 11, 2025	ALNYAlnylam Pharmaceuticals	$243.38	10.12%	Michael UlzMorgan Stanley 66%	268 284	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 9, 2025	ALNYAlnylam Pharmaceuticals	$243.38	31.48%	Joseph StringerNeedham 69%	320 320	Previous Buy Current Buy	Get Alert
Apr 2, 2025	ALNYAlnylam Pharmaceuticals	$243.38	105.44%	Patrick TrucchioHC Wainwright & Co. 68%	500 500	Previous Buy Current Buy	Get Alert
Mar 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	40.52%	Greg HarrisonScotiabank 78%	338 342	Previous Sector Outperform Current Sector Outperform	Get Alert
Mar 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	45.04%	Joshua Smith Redburn Atlantic 74%	353	Previous Initiates Current Buy	Get Alert
Mar 31, 2025	ALNYAlnylam Pharmaceuticals	$243.38	41.75%	Paul MatteisStifel 57%	300 345	Previous Buy Current Buy	Get Alert
Mar 24, 2025	ALNYAlnylam Pharmaceuticals	$243.38	34.77%	Jessica FyeJP Morgan 68%	280 328	Previous Neutral Current Overweight	Get Alert
Mar 21, 2025	ALNYAlnylam Pharmaceuticals	$243.38	44.22%	David LebovitzCitigroup 66%	338 351	Previous Buy Current Buy	Get Alert

Recent Analyst Stock Rating News

NeoVolta Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

NeoVolta will report Q4 earnings Sept. 23; analysts expect a 9-cent loss and $1.27M revenue.

PRO

RBC Capital Maintains Outperform on OceanaGold, Lowers Price Target to C$66

RBC Capital analyst Harrison Reynolds maintains OceanaGold (TSX:OGC) with a Outperform and lowers the price target from C$70 to C$66.

PRO

RBC Capital Maintains Outperform on K92 Mining, Raises Price Target to C$45

RBC Capital analyst Harrison Reynolds maintains K92 Mining (TSX:KNT) with a Outperform and raises the price target from C$44 to C$45.

PRO

RBC Capital Maintains Outperform on DPM Metals, Raises Price Target to C$65

RBC Capital analyst Harrison Reynolds maintains DPM Metals (TSX:DPM) with a Outperform and raises the price target from C$60 to C$65.

PRO

RBC Capital Maintains Sector Perform on Centerra Gold, Lowers Price Target to C$28

RBC Capital analyst Harrison Reynolds maintains Centerra Gold (TSX:CG) with a Sector Perform and lowers the price target from C$30 to C$28.

PRO

Oppenheimer Reiterates Outperform on James Hardie Industries, Maintains $36 Price Target

Oppenheimer analyst Tyler Batory reiterates James Hardie Industries (NYSE:JHX) with a Outperform and maintains $36 price target.

PRO

RBC Capital Maintains Sector Perform on Ivanhoe Mines, Raises Price Target to C$16

RBC Capital analyst Sam Crittenden maintains Ivanhoe Mines (TSX:IVN) with a Sector Perform and raises the price target from C$15 to C$16.

PRO

Oppenheimer Reiterates Outperform on Forgent Power Solutions, Maintains $60 Price Target

Oppenheimer analyst Noah Kaye reiterates Forgent Power Solutions (NYSE:FPS) with a Outperform and maintains $60 price target.

PRO

RBC Capital Maintains Outperform on Hudbay Minerals, Raises Price Target to C$48

RBC Capital analyst Sam Crittenden maintains Hudbay Minerals (TSX:HBM) with a Outperform and raises the price target from C$40 to C$48.

PRO

RBC Capital Maintains Sector Perform on Freeport-McMoRan, Raises Price Target to C$85

RBC Capital analyst Sam Crittenden maintains Freeport-McMoRan (TSX:FCXS) with a Sector Perform and raises the price target from C$73 to C$85.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website